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The CONSORT (CONsolidated Standards Of Reporting Trials)
2010 guidelines (http://www.consort-statement.org/consort-2010)
were developed to improve the reporting of parallel-group random-
ized controlled trials, whereby compliance with established
standards can be demonstrated via completion of the CONSORT
2010 checklist (Schulz et al., 2010). Leading medical journals have
endorsed this initiative, which has undoubtedly improved the con-
duct and reporting of clinical and health care research. Research in
the field of sports nutrition and exercise metabolism stands to benefit
from similar standards, but it commonly involves research designs
other than parallel-group trials, such as cross-over experiments.
A CONSORT extension covering randomized cross-over
trials has now been published (Dwan et al., 2019), with a revised
checklist that focuses on issues of primary relevance to clinical
trials involving medicine or health care outcomes. However,
such issues specific to clinical trials may have different rele-
vance when considered relative to the tightly controlled, labo-
ratory-based, mechanistic experiments that are common in
exercise science. For example, cross-over designs may involve
order effects between assessments; in medical trials, this tends to
occur most commonly due to the treatment or intervention itself,
requiring a sufficient wash-out interval before repeated assess-
ments. By contrast, the carry-over effect in sports nutrition
research is commonly related to the assessment itself, which
often tends to be more invasive or demanding for the participant
than a snapshot of health status. Indeed, exercise tests of human
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performance are particularly prone to learning or fatigue effects
and even physical adaptations that can persist for weeks or
months after the first test. For example, the so-called “repeated
bout effect,” which describes how a single exposure to
unaccustomed physical exercise that induces muscle damage
can impart profound and lasting protection from similar exercise
in the future (Byrnes et al., 1985; McHugh et al., 1999).
Participants in exercise trials may also be elite athletes whose
habitual levels of physical activity (and diet) may show pro-
found variation over time (i.e., periodization), thus further
complicating the interpretation of longitudinal studies.
The PRESENT (Proper Reporting of Evidence in Sport
and Exercise Nutrition Trials) 2020 checklist (see Appendix)
has therefore been adapted from the CONSORT guidelines to
specifically address the unique combination of challenges and
opportunities facing researchers within the broad fields of sports
nutrition and exercise metabolism. This current paper complements
and expands upon the CONSORT checklist by providing emphasis
and examples that are commonplace or of greatest relevance to
research in this subject area. The PRESENT 2020 checklist was
designed with consideration of the need to minimize the burden on
submitting authors while ensuring that standards for reporting
research are met; it should allow researchers to quickly determine
whether all relevant information is included in their manuscript. Of
course, it is possible to meet all the factors on the checklist despite
either having conducted a poor study and/or having reported a good
study poorly, whereas some items on the checklist may not be
applicable even for rigorously conducted research. Nonetheless,
consideration and discussion of the factors identified in the check-
list should improve the reporting of exercise- and nutrition-related
research in the immediate future and has the potential to enhance
the design and conduct of trials in the long term.
The following sections expand on and justify the rationale for
each of the items included in the associated submission checklist.
Title
1a The title should accurately reflect the primary findings of the
study, preferably via an informative statement (e.g., “Caffeine
improves 200 m swimming time in elite swimmers” rather than
“The effects of caffeine ingestion on swimming”). Correlation does
not infer causality, so causal language should be reserved for the
title of experimental research only (e.g., terms such as impaired,
resulted, or improved), whereas observational research should
employ appropriate noncausal statements (e.g., terms such as
related, correlated, or associated). Titles should specifically iden-
tify the measured variable(s) rather than proxy or indirect measures
(e.g., “blood lactate production” or “blood glucose clearance”
should not be stated when only blood concentrations of the
respective metabolites have been assessed).
1b The title should identify the study population if characteristics
are directly relevant to the study design (e.g., sex and/or training
status). If using nonhuman models, the species should be stated.
Abstract
Some readers may not have access to the full paper, so a properly
formatted and well-written abstract is imperative. Authors should
give priority to information about the current study rather than
using the abstract for an extensive background or rationale.
2aMethods: Key information regarding the study design, methods,
and population should be summarized to enable broad understand-
ing of the study from the abstract.
2b Results: Readers are interested in extracting key data that reflect
the main findings of the study. The abstract should present data
(e.g., the absolute magnitude of values and the size/precision of
effects—specifying which measures of central tendency and vari-
ability are stated) rather than simply stating the presence, absence,
or direction of effects. The presentation of p values or similar
inferential statistics is no substitute for reporting actual data
(Maughan, 2004).
2c Conclusion: Priority should be given to the reporting of results
as per the previous section, with only a brief concluding statement
thereafter. A concise conclusion based on what was actually
measured in the study is preferred to speculative interpretations,
with cautious use of language to avoid hyperbole or improper
inference of causality (Brown et al., 2013). It is not appropriate or
necessary to identify further research priorities here.
Introduction
3a This section need not provide a comprehensive review of the
subject area, as relevant review articles can be referenced when
briefly introducing underlying theory, processes, and/or mechan-
isms. Priority of publication should be recognized—recent pub-
lications that simply confirm earlier findings should not be cited.
Therefore, the primary focus should be on what has been done
already, particularly the most relevant previous studies, ensuring a
fair balance of different perspectives wherever current evidence is
equivocal. It should be clear to the reader both what new informa-
tion the study aims to provide and why that information is
important. The former most commonly means identifying novelty
(i.e., what will this study show that has not been shown before) but
could also mean justifying why replication of a past study is
necessary. If the novel element of a study relies on a long list
of qualifiers (e.g., the effect of A on B has already been established
but not within population C and context D), then the “Introduction”
should justify why those qualifiers are interesting and warrant
further investigation (i.e., What is important about population C
and/or context D?). Thus, the reader should have a clear under-
standing of the rationale for the work.
3b A formal hypothesis may not always be appropriate for work of
an exploratory or qualitative nature, but the “Introduction” should
conclude with some form of clear aim, objective, or research
question (i.e., sufficient to express the central question and present
the primary variables under investigation).
Methods
4 Ethics
The details regarding ethics approval should provide adequate
reference to the approving body to enable verification of approval
if needed. Authors are encouraged to report the ethics committee
approval number (if available) and date of approval. Informed
consent should be explicitly noted for human trials where
relevant—and carefully justified for any trials where deception or
testing of participants without prior consent was warranted (Harriss
et al., 2017). In the case of participants below the legal age of
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consent, their assent and the consent of their parent or guardian
should be obtained. Pretrial registration of studies that qualify for
recognition as “Clinical Trials” is strongly encouraged, and details
of access to the Clinical Trials Registry should be provided.Where a
paper reports data that have been collected during routine monitor-
ing of individuals as a condition of their employment or participation
(e.g., athletes or military populations), a clear statement about the
source of data and the reasons for the absence of prior approval by an
appropriate body, such as their requirement as a condition of
employment, must be made explicitly (Winter & Maughan,
2009). In such situations, it may be appropriate to introduce
some degree of separation into the process, such as a gatekeeper
to maintain the anonymity and/or confidentiality of data.
5 Design
Full details of the research design should be summarized early in
the “Methods” section to establish context for the reader, using
common terminology and nomenclature (e.g., parallel trial/cross-
over, randomized, counterbalanced, blinding, observational, etc.)
both to provide a top-line overview from the outset and to facilitate
accurate data extraction for those conducting future systematic
reviews and meta-analyses. All descriptive work, including sur-
veys and case studies, should be identified as observational
research. If the data presented in the paper are from a secondary
analysis of a wider/previous study rather than from primary
research, this should also be clearly identified in the introductory
information about the study design, with commentary around
whether the study was specifically or adequately designed for
the purposes reported in the present paper and whether any data
are replicated from an earlier publication.
6 Sampling
6aRecruitment methods, eligibility (inclusion/exclusion) criteria, and
sampling methods should be explained, ideally providing a rationale
for the target population. In particular, authors of case studies must
justify the interest in, or choice of, their unique participant(s). If the
study authors intentionally recruit an unrepresentative proportion of
male and female participants, this should be justified.
6b To provide full transparency around the population to which the
study findings may be generalized, a thorough account of partici-
pant characteristics is essential. All data should be reported with
appropriate precision relative to the measurement tool and units in
question (Kordi et al., 2011); for example, it is unnecessary to
record or express age in decimal years or with greater precision
than the integer (e.g., it is appropriate to report an age in years as 25
rather than 25.24). The choice of which demographic, anthropo-
metric, or lifestyle variables to report should be considered in terms
of relevance to trial interpretation and generalization within this
field (e.g., training status, competitive level, habituation to diet).
The term “elite” is commonly misused when describing athletes:
Descriptive terms should be used appropriately and qualified by
information that is objective (e.g., personal best for a relevant
event, level of international/national representation, ranking, or
point score where it has global meaning, current scores from a
quality assured test battery, etc.).
6c The study setting should be described both in terms of laboratory-
versus field-based testing and the region/site(s) of data collection. If
data are collected across multiple independent laboratories, details of
which measurements were made at each location should be pro-
vided, with relevant reliability data specific to each site. Start and end
dates of testing are also required. Appropriate environmental data
(e.g., temperature, relative humidity, altitude) should be stated where
these are relevant to interpretation of the study.
6d Justification should be provided for the size of the sample that
was recruited and tested. The pragmatic nature of labor/time-
intensive, and often invasive, experiments in this field is such
that sample size is sometimes dictated by the availability of human
volunteers and/or resources. It is also the case, however, that it can
be unethical to include more participants than are necessary to test
the hypothesis. An estimation of the statistical power/precision
should therefore be provided based on the minimal worthwhile
effect and available sample size (Batterham & Atkinson, 2005),
and all components of the calculations should be clearly justified
and reported in sufficient detail to enable replication (i.e., alpha,
beta, minimal worthwhile effect, variance estimate—e.g., the SD of
pre-to-post change). Post hoc power estimations (based on the
effect size observed in the study itself) should be avoided. It should
also be clearly expressed whether the hypothesis is of a “superior-
ity” nature, where one treatment/intervention is hypothesized to
differ from the control or another intervention, or whether the study
is more akin to an “equivalence trial” in which one treatment/
intervention is deemed to be of similar effectiveness to another
intervention—but perhaps simpler, less costly or less invasive in
some way. In the latter situation, the null hypothesis testing
procedure is not appropriate—p > .05 should never be used to
infer that there is “no difference” between two or more sample
estimates (Assel et al., 2019) nor should p values marginally greater
than .05 be interpreted as a “trend.”
Sample size estimations may be based on null hypothesis
testing or the desired width of a confidence interval, but the choice
should be justified. The “Discussion” section may provide authors
with further opportunity to frame their statistical inferences along-
side recent concerns about replication of study results. For example,
the notion that an observed effect size is large merely due to the
sampling error associated with a relatively small sample—an issue
known as the “winner’s curse”—may be assisted by the reporting of
statistics such as the “Surprisal (S) value” (Greenland, 2019).
Importantly, inadequate sample sizes are not necessarily justified
merely because the population in question are rare or difficult to
recruit (e.g., elite athletes) or that similar sample sizes have been
used in previous publications—such instances may be better pre-
sented as pilot work or case studies, or alternatively the sample size
could be supplemented by including data from a broader population
(e.g., subelite athletes), unless there is reason to expect the primary
outcome to respond distinctly in the more focused sample.
7 Interventions
The intervention/treatment is arguably the single-most important
element of methods reporting; even seemingly trivial details of the
independent variable may be critical to a proper understanding of
the responses attributed to the groups/conditions. For nutritional
compounds with complex ingredients, a side-by-side comparison
(possibly tabulated) is often advisable for clear and comprehensive
reporting. Critically, it is wholly inadequate to simply provide a
manufacturer/product name for a scientific report because the
actual composition of such commercially available goods may
be proprietary, reformulated, discontinued, and/or different from
the reported composition of each batch produced; the prospective
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scientific value of the results depends entirely on the reader being
able to establish what the intervention involved. For this reason,
there should be careful consideration of whether the nutritional
compound under investigation requires analysis to verify both that
the reported ingredients are present in the quantities stated and that
undisclosed ingredients or contaminants are absent (in some cases,
it may be that certain physiological measurements can be used to
verify the efficacy of the supplementation protocol and so may be
capable of verifying the mere presence or absence of key ingre-
dients between treatments). Simple products that are formulated in-
house (e.g., glucose solutions prepared according to a clear proto-
col) may not require such verification, but transparent and credible
investigation of commercially available products often requires
such checks of the specific batch used in the research project.
Lastly, where particular nutritional compounds or blends have been
selected for examination, it can be informative to explain the
rationale for decisions regarding the choice of intervention relative
to outcomes (e.g., see Approach to the Research Question subsec-
tion in Bailey et al., 2011).
8 Measurements
8a The primary outcome measures intended to answer the stated
research questions should be clearly specified. The eventual con-
clusions and interpretation should then be based on these prestated
primary outcomes (especially in the case of null results), rather than
focusing on outcomes according to which were most responsive or
were consistent with the hypothesis. The categorization of vari-
ables that are measured on a continuous scale (“dichotomania”)
should be avoided unless there is a robust reason to do so (Senn &
Julious, 2009).
8b A rationale for the selected measurement tools should be
provided. Metrics pertaining to dietary analysis and/or exercise
testing are frequently involved in sports nutrition research. Regard-
ing the former, the method of dietary assessment should be
precisely described (e.g., self-report vs. direct measure, prospective
vs. retrospective collection, weighed vs. estimation from household
measures quantification), and the limitations should be considered,
along with full details of the name and version of any dietary
software used. Regarding the latter, information of interest includes
the nature of the test (e.g., exercise capacity/time-to-exhaustion vs.
exercise performance/time trial), the familiarity/familiarization of
participants with the testing protocol and whether intensity is
absolute or relative to another parameter (e.g., %V˙O2max). Pro-
tocols that aim to measure sports performance should be valid,
reliable, and sensitive (Currell & Jeukendrup, 2008). In all cases,
the degree of measurement error associated with each outcome
should be expressed using relevant reliability statistics (Atkinson&
Nevill, 1998). For biochemical assays, reliability data should
ideally be derived from in-house analysis rather than using the
intra- or inter-assay reliability reported by the manufacturer. Re-
searchers should note whether clinical chemistry analyzers in-
tended for diagnostic use provide the precision necessary for
research purposes.
8c Authors should clearly identify and justify the smallest differ-
ence between treatments that is deemed to be meaningful, which
should be consistent with the sample size estimates presented under
Item 6d and be taken into account when interpreting data (i.e., an
effect smaller than that deemed meaningful should not then be
overinterpreted, even if it happens to be statistically significant). It
is important to note the distinction between the smallest worthwhile
effect or association and the smallest detectable effect (de Vet et al.,
2006). The former value, often termed the “target difference” or
“minimal clinically important difference” (MCID), is the value of
change or association that is deemed to be important for partici-
pants, athletes, or patients. Ideally this threshold would be based on
known relationships between change in the outcome of interest and
change in real athletic performance, physiological adaptation, or
morbidity/mortality in the context of clinical trials. Nevertheless,
such knowledge can be difficult to derive. We refer readers to the
DELTA and DELTA2 publications for a full treatment of this topic,
including all the approaches for arriving at a MCID (Cook et al.,
2014, 2018).
The smallest detectable change is a threshold based on the
likelihood of a change in an individual athlete or patient being due
to random within-subjects (test–retest) error or not, with a certain
coverage probability. Although this may be useful for monitoring
individuals, it is important to note that the smallest detectable
change and the MCID might be different in magnitude. For
research purposes, the MCID and the approaches for deriving
this value are most important. Similarly, with regard to correla-
tions, interpretation should always consider that the strength,
direction, and form of a relationship; for example, a weak, inverse,
linear relationship (e.g., r = −.1) may be of limited meaning or
utility irrespective of whether it is statistically significant.
9 Randomization
Randomization in a trial can be a critical component of experi-
mental validity, yet it is one where important details are often
unreported. Full details should be provided to identify precisely
how the random allocation sequence was generated and imple-
mented and by whom (Schulz & Grimes, 2002a, 2002c, 2002e).
For example, such details could include the type of random
allocation sequence, the allocation ratio, and details of any mini-
mization or restriction (e.g., stratification, blocking, and block
size), with clear identification of the individuals responsible for
generating/managing the allocation sequence, recruiting/enrolling
volunteers, assigning treatments, conducting data collection, and
analyzing samples.
10 Blinding
Although experiments are commonly designed and instigated on the
basis of a working hypothesis regarding the anticipated answer to a
prestated research question, it has been recognized for over 150 years
that measurements should be made without any preconceived ideas or
a priori assumptions regarding the expected results (Bernard, 1865).
This reasoning forms the basis for themodern concept of experimental
blinding, which aims to control the conscious or subconscious biases
of experimenters, participants, and/or outcome assessors by keeping
them unaware of the expected response to a given stimulus (Schulz &
Grimes, 2002b). Blinding is a technique that allows researchers to
conduct the study without preconceived expectations of the results,
despite the existence of a working hypothesis. This ideal can be
achieved by concealing the treatment allocation and/or the purpose of
the experiment from anyone involved who can conceivably influence
the measurements being made.
Although blinding is important at various levels, when outcome
measures are subject to conscious or subconscious control, the
blinding of participants becomes a critical issue. Examples of
such measures in the field of sport nutrition and exercise metabolism
PRESENT Submission Checklist 5
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include metrics around physical performance (e.g., maximal volun-
tary muscle contraction, time to fatigue in an exercise task) or
subjective perceptions (e.g., rating of perceived exertion or
soreness). These outcome measures might be compared with objec-
tive physiological variables that are generally less prone to expec-
tancy/placebo effects (e.g., changes in systemic metabolite
concentrations or substrate utilization during exercise). However,
some interventions are difficult or essentially impossible to truly
blind (e.g., cryotherapy or exercise) and in some cases the partici-
pants’ awareness of the intervention is pivotal to the proposed
mechanism of action (e.g., psychological interventions). In such
situations where blinding of treatment allocation is impossible or
undesirable, it may be justified to blind participants to the purpose of
the experiment by assessing the primary outcome measure covertly
within the context of the wider study. For example, participants may
be offered a meal upon completion of testing, after which consent
can be sought post hoc to determine natural ad libitum food intake
based on any left-over/uneaten food. Examples of the various levels
of blinding are provided in Table 1.
When performing a blinded study, it is especially important
to assess the success of blinding. For example, a treatment can be
implemented in a blinded manner whereby participants are not
informed of treatment allocation, and every effort can be made to
conceal treatment allocation using placebo/control conditions that
are taste and texture-matched, using opaque containers, anon-
ymized labels, sham treatments, or even novel methods of
administration (e.g., nasogastric delivery of nutrients; Funnell
et al., 2019). However, the trial is only truly blinded in the sense
that conscious/subconscious bias is controlled if participants are
unaware of their treatment allocation. Therefore, beyond the
above-mentioned methods intended to conceal treatment alloca-
tion, the success of blinding can easily be assessed by way of a
formal exit questionnaire. For example, for a cross-over design in
which each participant has the opportunity to experience and
compare conditions, this can be achieved via three straightfor-
ward binary “yes/no” responses: (a) did the participant (or
experimenter/assessor) detect any difference between treatments;
if yes, (b) did the they feel able to identify their treatment
allocation; if yes, (c) did they correctly identify their treatment
allocation? For interventions where participants may conceivably
detect differences between treatments, it may also be informative
to survey their prior knowledge, preconceptions, and beliefs
about the expected effects of treatment.
Ultimately, research should only be reported as blinded if the
researcher is confident that participants were not aware of treatment
allocation; if it transpires that a proportion of the overall cohort
were able to distinguish treatments, then it may be informative to
report the extent to which observed responses may have been
influenced by the success of blinding. Although blinding can
reduce bias in experiments, it does not overcome a lack of
randomization, which is a common misconception (Schulz &
Grimes, 2002b). In addition, if complete blinding to a treatment
is difficult or impossible and exercise performance is the primary
outcome, then exercise testing should follow recommendations to
withhold relevant performance feedback during the exercise tests
(Currell & Jeukendrup, 2008).
11 Standardization
Standardization of participants’ behavior and environment ahead
of testing and during data capture can reduce the variability in
baseline measurements both between and within individuals.
This can increase the ability to detect true effects with relatively
small sample sizes, effectively increasing the signal-to-noise
ratio. Key considerations include the length of time of pretest
controls and whether standardization is performed across differ-
ent participants (i.e., controlling interindividual variation) or
only within-participants (i.e., controlling intraindividual varia-
tion), which largely depends on whether the research involves a
parallel or cross-over design. Common parameters around par-
ticipant behavior/characteristics to control within the field of
sport nutrition and exercise metabolism include physical activity,
diet/hydration, medication/supplement use, and menstrual cycle.
It should be clearly stated whether this control was directly
facilitated by the investigators (e.g., providing meals) or, if
not, whether any objective assessments were employed to verify
successful replication (e.g., heart rate monitoring to confirm
abstinence from intense physical exertion prior to testing). If
such monitoring has been completed, it is often informative to
report the data to provide future context when contrasting the
Table 1 Summary of Various Forms of Experimental Blinding
Type of
blinding Description Rationale
Open label All categories of individuals (experimenters, partici-
pants, and outcome assessors) are aware of who has
received which intervention throughout the trial.
Some interventions are impossible to truly blind
(e.g., exercise) or participants’ awareness of the
intervention is inherent to the research question.
Single blind One category of individuals (normally the participants,
but potentially the experimenters or outcome asses-
sors) is unaware of who has received which inter-
vention throughout the trial.
When participants are blinded:
• Less likely to have biased psychological or physical
responses to the intervention.
• Less likely to seek additional adjunct interventions.
• More likely to comply with intervention.
• Less likely to leave the trial without providing data.
Double blind Experimenters, participants, and outcome assessors
are all unaware of the intervention assignments during
the trial.
When investigators/assessors are blinded:
• Less likely to transfer inclinations or attitudes to
participants.
• Less likely to have biases affect outcome assess-
ments, especially with subjective outcomes.
Triple blind Experimenters, participants, and outcome assessors
are all unaware of the intervention assignments during
the trial and during data analysis.
Less likely to have biases affect statistical analyses and
interpretation.
6 Betts et al.
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results with other trials. For example, even if diet was closely
matched between conditions, readers may benefit from knowing
whether nutritional interventions were contrasted against a back-
ground diet that is relatively high or low in energy or other
nutrients. A more detailed summary of methods to implement
and report dietary standardization techniques is provided else-
where (Jeacocke & Burke, 2010).
Variance in the presence and stages of menstrual cycle should
be considered where relevant: There are numerous approaches to
control for this factor, each potentially justified based on a balance
of internal and external validity. A rationale should be provided to
explain whether menstrual phase was controlled for within or
between participants and which phase of the cycle was selected
to minimize confounding influences and/or to be most representa-
tive. If a specific phase of the menstrual cycle is stated, it should be
made clear whether this was based on self-reported dates or
measurements of sex hormones.
For further information about the benefits and techniques for
the pre- and during-trial standardization of factors such as recent
exercise, acclimation, noise/distractions, encouragement, and the
awareness of the passage of time or previous results, the reader is
referred to other reviews (Burke & Peeling, 2018; Currell &
Jeukendrup, 2008).
12 Order Effects
The potential for order effects between serial trials of the same
participant should be assessed and reported, particularly during
studies using a repeated-measures crossover design. Critically, if
an initial assessment under one condition exerts lasting effects or
adaptations that exceed the wash-out interval before the repeat
assessment under the other condition, then randomization and
counterbalancing of treatment order do nothing to prevent the
problem of order/period/sequence effects. This scenario is par-
ticularly problematic if there is any interaction between the effect
of the intervention and the magnitude of the carry-over effects
between measurements; indeed, if order effects are apparent, then
no antidote can rectify the problem and isolate the effects of the
intervention. Examples of preemptive measures to minimize the
likelihood of order effects include the following: allowing ade-
quate washout between assessments; providing adequate prior
familiarization with testing; and/or sampling a population already
accustomed to the protocol and thus unlikely to exhibit marked
learning or fatigue effects between exposures (e.g., using trained
athletes for exercise tests). However, more extended wash-out
periods between assessments (i.e., weeks to months) could induce
training/detraining effects and/or introduce seasonal variance as
confounders.
Experiments where order effects are apparent are not neces-
sarily unfit for publication, but the order effect must be clearly
referenced when reporting outcomes. Exploring data for order
effects may take the form of applying similar statistical techniques
as used for the primary analysis between conditions but with
reference to the sequential assessments (Wellek & Blettner,
2012), with due consideration that effects of the intervention
and treatment order may interact (e.g., the placebo may be consis-
tently inferior only when applied in the first trial). However, given
the complexities of such statistical analyses and that the absence of
detectable differences between sequential tests does not necessarily
infer that they were equivalent, it may be worthwhile inspecting
individual data for evidence of any systematic changes according to
trial order.
13 Statistics
13a The comparisons that will inform primary inferences about the
study data should be identified, with statistical approaches described
in adequate detail. In particular, there should be consistency between
the proposed approach, the rationale presented in the Introduction,
and the data reported. For example, if the study has been designed to
contrast responses over time to an intervention versus a placebo, the
analysis should target the differences between those conditions
rather than the relative presence or absence of changes from baseline
within each condition (Bland & Altman, 2015).
13b Any unplanned or exploratory analyses should be clearly distin-
guished from the primary purpose and analysis, with justification
provided for any interim analysis or potential conditions under which
a trial might stop, including consideration of intention-to-treat versus
per-protocol analyses. In particular, be cautious of subgroup analysis
with stratification at baseline because regression to the mean can
compromise inferences (Thomas et al., 2019). Similarly, stratifying on
the study outcome for responder/nonresponder analysis is fraught
with difficulties and pitfalls (Atkinson&Batterham, 2015). These and
other common statistical pitfalls are listed along with relevant ex-
amples, further explanation, and possible solutions in Table 2.
13c Researchers should be aware of the assumptions underlying
each selected statistical approach and report clearly how any
departures from these assumptions were handled. The most impor-
tant data to check for approximate “normality” are typically the
residuals of the selected statistical model. In the context of a paired t
test, these data are the individually paired change scores or
differences. Furthermore, parametric analyses may often be robust,
even when raw data are nonnormally distributed. Any data trans-
formation should be clearly justified (Bland & Altman, 1996).
Blanket logarithmic transformation of data without checking first
whether the data require or benefit from this transformation is not
good practice. Researchers should also be aware that statistical tests
of skewness (where the null hypothesis is that data are “normally”
distributed) are prone to problems when sample sizes are small.
Similar to the time-series design described under item 13a, in which
there are repeated measures over serial time points within each
condition, it may also be necessary to adjust for baseline differ-
ences in the primary outcome measure (i.e., analysis of covariance;
Vickers, 2005). In this respect, authors should interpret any
differences in pre-to-post change carefully when there are mean-
ingful differences between groups or conditions in the study
outcome(s) at baseline—such a problem may not be rectified by
calculating percentage changes from baseline or by interpreting a
Group/Condition × Time interaction term (Vickers, 2001).
Results
14 Participant Flow
14a Depending on the complexity and nature of the experimental
design (e.g., multiple follow-ups with poor adherence, many with-
drawals and exclusions), it may be appropriate to present a
flowchart of the numbers of participants who were recruited,
eligible, enrolled, randomized, assigned, received treatment, and
analyzed at each time point. For more straightforward designs, it
may be possible to simply communicate this information within
text, but it remains essential to clearly identify the number of
participants (denominator) included in each analysis (i.e., specific
to each time point and outcome measure as required). In particular,
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clear reasons should be provided for any exclusions from the final
data set, with changes from original treatment assignment acknowl-
edged and justified (Schulz & Grimes, 2002d).
14b Researchers should avoid pooling data for participants over
multiple experimental conditions or groups and analyzing the data
without modeling these conditions and groups, a problem known as
“pseudoreplication” (Lazic, 2010). Examples of such transgres-
sions include the pooling of data for 10 participants across three
conditions and then calculating correlation coefficients between
measured variables as n = 30 rather than n = 10. This approach
breaks the assumption of independence of cases, inflates degrees of
freedom, and can be misleading: Indeed, within-subjects correla-
tions between two variables measured over time may be different
from between-subjects correlations between two variables mea-
sured at the same point in time.
15 Outcomes
15a Data should be reported according to the International System
of Units (i.e., SI units) or accepted derivatives. An exception, as
commonly applied in nutrition science, are units for measuring
energy intake or expenditure, where either kilocalorie or kilojoule
may be used. The measures of central tendency and variability used
to describe each data set should be clear, as well as and how effects
and estimated precision are expressed (e.g., 95% confidence
interval). If p values are to be reported, then it should be recognized
that those close to but higher than .05 do not indicate a “trend” or an
approach to significance, whereas a value equal to 0 is not possible
(Assel et al., 2019). Units of measurement should not be used in
place of variables when describing data: for example, data should
be referred to as energy intake rather than kilojoule (or calorie)
intake.
15bWherever reasonable, there should be an effort to present the
full range of observed data (i.e., individual measurements or
responses) to illustrate the consistency of effects rather than
just group summary statistics. Any normalization of measure-
ments according to another variable or time point (e.g., % change
or g/kg) requires careful consideration and justification, ideally
complemented by some reporting of the original data so the reader
can interpret findings within the context of the unadjusted/abso-
lute values. Nevertheless, participants who produce a result that
differs in the direction or magnitude of the group mean outcomes
should not be labeled as “nonresponders” to the treatment, based
solely on this solitary observation. Where the likelihood of
individual variability to a treatment is anticipated, the study
design could include features such as repeated testing of the
same treatment or the collection of mechanistic data that might
corroborate true differences in physiological/psychological re-
sponses (i.e., biological samples that may verify or explain the
efficacy of effect). The possibility that day-to-day variability in
the primary outcome measure explains divergent results should be
considered.
15c In the interest of balanced reporting, any unforeseen negative
consequences, harms, or unintended consequences must be fully
disclosed alongside the primary results (rather than noted in “Dis-
cussion” section). For example, unexpected gastrointestinal issues
associated with a nutritional supplement should be reported in full,
irrespective of whether primary outcomes, such as metabolic and
ergogenic responses, were negatively affected.
Discussion
16a Interpretation—The Discussion should maintain focus on the
new data generated by the research rather than extensively review-
ing the wider literature, although it should be made clear how the
novel insight provided by the research complements and advances
existing evidence. More speculative suggestions that go beyond the
data may be acceptable in this section, but must be clearly identified
as such. As per the Title and Introduction, special care should again
be taken in this section to ensure the choice of language avoids
hyperbole or improper inference of causality.
16b Generalization—Consideration should be given to how well
the outcomes of the research project can be generalized beyond the
population and context in which they were measured. The fact that
the research involved a relatively homogenous or heterogeneous
sample is neither a strength nor a limitation in itself, but it has
implications for how broadly or specifically findings may translate
to others.
16c Strengths and limitations—A succinct and truthful summary of
the strengths of the design, conduct, and outcomes of the study
should be integrated throughout the Discussion. Not only does this
provide the reader (and reviewer) with an opportunity to reflect on
the confidence they place in the study findings but, by drawing
attention to the careful methodological and reporting features of the
study, other researchers will be encouraged to adopt such measures
in their future work. Potential sources of error or confounding
variables should also be acknowledged where relevant throughout
the Discussion, allowing conclusions to be tempered accordingly. A
more integrated reference to limitations is usually preferred to a
stand-alone paragraph toward the end of the Discussion that lists a
selection of weaknesses, which are not reflected in the overall
interpretation. In any case, the final conclusions need to reflect a
balance of all characteristics noted in this section.
Other
17 Disclosures
The onus is on the authors to determine which relationships they
believe others might conceivably consider to represent conflicts of
interest or that should be disclosed for any other reason. This could
include, but is not limited to, industry relationships, employment/
shares, provision of nutritional supplements or consumables, book
sales, or any other personal biases.
18 Protocol
Any publicly registered or published protocol should be refer-
enced, and deviations from any prior records should be listed and
explained.
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